Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 404 across all filing types
Latest filing 2023-03-01 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Revive Therapeutics Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended December 31, 2022. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3031 characters, which is relatively short and consistent with a certification letter rather than a full report.
2023-03-01 English
Interim MD&A - English.pdf
Annual Report Classification · 100% confidence The document is titled 'Independent Auditor’s Report' and contains detailed audited financial statements for QC Copper and Gold Inc. for the years ended October 31, 2022 and 2021. It includes the auditor's opinion, basis for opinion, responsibilities of management and auditors, and comprehensive financial statements such as statements of financial position, loss and comprehensive income, changes in equity, and cash flows. The presence of an auditor's report and full financial statements for a fiscal year indicates this is an annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-03-01 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains unaudited condensed interim consolidated financial statements including statements of financial position, comprehensive loss, cash flows, and changes in shareholders' equity. It covers a six-month period ending December 31, 2022, and includes detailed financial data and notes. The presence of interim financial statements with substantive financial data and analysis indicates this is an Interim / Quarterly Report rather than an announcement or certification. The document length is substantial (15,000 characters), and it is not merely a notice or announcement of a report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-03-01 English
News release - English.pdf
Regulatory Filings
2023-02-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new research collaboration agreement between Revive Therapeutics Ltd. and PharmaTher Holdings Ltd. It discusses the development of an MDMA transdermal patch and provides background on the companies and their research programs. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not an annual report, interim report, earnings release, or any form of detailed financial or governance report. It is a corporate announcement about a collaboration agreement, which fits best under the category of a general regulatory announcement or miscellaneous filing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7607 characters) and content support this classification with high confidence.
2023-02-03 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, underwriter information, distribution dates, purchaser information, types of securities distributed, and compensation related to the distribution. The form is a regulatory filing used in Canada to report exempt distributions of securities. It is not a financial report like an annual or interim report, nor is it an earnings release or management discussion. It is a specific regulatory filing related to securities distribution compliance. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-01-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.